

## Financial Tear Sheet

### Corporate Profile

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime, Inc.'s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. Together with our subsidiaries, we are advancing late-stage pivotal trials and a robust pipeline which includes the following programs:

- OpRegen® is in a Phase I/IIa development for the dry form of age-related macular degeneration (dry-AMD) through subsidiary Cell Cure Neurosciences Ltd.
- Renevia®, our proprietary cell delivery matrix designed to facilitate the stable engraftment of transplanted cells, is in a pivotal clinical trial in Europe for HIV-associated lipoatrophy.
- AST-OPC1 is in a Phase I/IIa trial for spinal cord injury rehabilitation and AST-VAC2 is advancing toward clinical development for acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC), all pluripotent stem cell-based therapies being developed by its affiliate Asterias Biotherapeutics, Inc. (NYSE MKT: AST).
- OncoCyte (NYSE MKT: OCX) is developing a next generation of diagnostic tests that will be liquid biopsies using blood or urine samples. OncoCyte's initial liquid biopsy products will be confirmatory diagnostics for detecting lung, bladder, and breast cancer. OncoCyte's diagnostic tests are based on a proprietary set of genetic markers broadly expressed in numerous types of cancer.
- Technology healthcare (mHealth) solutions are being developed and marketed by subsidiaries LifeMap Solutions and LifeMap Sciences, Inc.
- cGMP-compliant human ES cell lines are available for research and clinical studies.
- BioTime's FDA-approved blood plasma expander Hextend® is marketed in collaboration with Pfizer Inc., in the United States and under an agreement with CJ Corporation in South Korea.

We are a publicly traded company listed on the NYSE MKT and TASE under the symbol BTX.

# Stock Performance

## BTX (Common Stock)

|                    |                       |
|--------------------|-----------------------|
| Exchange           | NYSE (US Dollar)      |
| Price              | <b>\$1.06</b>         |
| Change (%)         | <b>▼ 0.06 (5.36%)</b> |
| Volume             | 307,823               |
| 52 Week Low        | \$0.66                |
| Market Cap         | \$134,581,879         |
| Rolling EPS        | -0.65                 |
| PE Ratio           | N/A                   |
| Shares Outstanding | 126,964,037           |

Data as of 01/16/19 4:10 p.m. ET



## Recent News

### Date Title

- 01/09/19 AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
- 01/07/19 BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
- 01/04/19 BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

| <b>Filing Date</b> | <b>Form</b> |
|--------------------|-------------|
| 01/14/19           | S-4/A       |
| 01/09/19           | 4           |
| 01/09/19           | 3           |
| 01/04/19           | 4           |

## Management

|                               |   |
|-------------------------------|---|
| Michael D. West, Ph.D.        | Co-Chief Executive Officer                                  |
| Adi Mohanty                   | Co-Chief Executive Officer                                  |
| Russell Skibsted              | Chief Financial Officer                                     |
| François Binette, Ph.D.       | Head of Global Development                                  |
| Oscar Cuzzani, M.D.,<br>Ph.D. | Vice President of Clinical<br>Development                   |
| Judith Segall                 | Vice President of Administration and<br>Corporate Secretary |
| Hal Sternberg, Ph.D.          | Vice President of Research                                  |

Data provided by Nasdaq. Minimum 15 minutes delayed.